Entellus Medical raises $30 million
This article was originally published in The Gray Sheet
Expanded commercialization of the firm's FinESS endoscopic device for less invasive treatment of chronic sinusitis will be facilitated by a recently completed $30 million "Series D" financing round, announced Nov. 17. A portion of the funds will go toward expanded sales and customer support teams. The Minneapolis firm launched the 510(k)-cleared device in September 2008, and says it is now preparing for nationwide availability in 2010, as well as for overseas marketing. The funding was led by Essex Woodlands Health Ventures
You may also be interested in...
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.